Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q901 Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors
NCT05394103Phase 2Recruiting
- Sponsor
- Qurient Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mocaciclib in ovarian cancer, prostate cancer (PCa), Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+), endometrial cancer (EC), colorectal cancer (CRC), sponsored by Qurient Co., Ltd.. Started Aug 2022; status: recruiting.
02
Drugs
mocaciclib
03
Conditions
ovarian cancerprostate cancer (PCa)Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)endometrial cancer (EC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05394103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394103.